Novelos Therapeutics to present and webcast at Noble financial 4th annual equity conference

Newton, Massachusetts, (PresseBox) - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Harry S. Palmin, President and CEO of Novelos, will present at the Noble Financial 4th Annual Equity Conference on Monday, August 18, 2008. Mr. Palmin is scheduled to present at 11am PDT (2pm EDT) at the Interceptor Room. The event will be held at the Lowes Lake Las Vegas Resort, Nevada.

A live webcast of Mr. Palmin's presentation may be accessed via www.novelos.com The webcast will be archived for 90 days following the presentation.

Information about the conference is available at: www.noblemadmax.com

Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and a chemopotentiator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer.
NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed. For additional information about Novelos please visit www.novelos.com

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.